The pharmacotherapy of human aggression: A review

Journal of Pharmacy Practice

Volumn 9, Issue 2, 1996, Pages 133-143

  Caley, Charles F ^a,b  

^a Medfield State Hospital   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; COCAINE; ELTOPRAZINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LORAZEPAM; METOPROLOL; NADOLOL; NEUROLEPTIC AGENT; PHENCYCLIDINE; PIPERAZINE DERIVATIVE; PLACEBO; PROPRANOLOL; RISPERIDONE;

AGGRESSION; AGRANULOCYTOSIS; ANIMAL MODEL; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG POTENCY; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 0029942384     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/089719009600900210     Document Type: Review

References (70)

1. Corrigan PW, Yudofsky SC, Silver JM: Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Comm Psychiatry 44:125-133, 1993
2. Eichelman B, Hartwig A: The clinical psychopharmacology of violence. Psychopharmacol Bull 29:57-63, 1993
3. American Psychiatric Association: Report of the Task Force on Clinician Safety. Washington, D.C., American Psychiatric Association, 1992
4. Tardiff K: The current state of psychiatry in the treatment of violent patients. Arch Gen Psychiatry 49:493-499, 1992
5. Yudofsky SC, Silver JM, Jackson W, et al: The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143:35-39, 1986
6. Kravitz HM, Fawcett J: Serenics for aggressive behaviors. Psychiatr Ann 24:453-459, 1994
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C., American Psychiatric Association, 1994
8. Eichelman B: Neurochemical and psychopharmacologic aspects of aggressive behavior, in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress, vol 3. New York, NY, Raven Press, 1987, pp 697-704
9. Tardiff K, Sweillam A: Assault, suicide, and mental illness. Arch Gen Psychiatry 37:164-169, 1980
10. Binder RL, McNeil DE: Victims and families of violent psychiatric patients. Bull Am Acad Psychiatry Law 14:131-139, 1986
11. Rossi AM, Jacobs M, Monteleone M, et al: Violent or fear-inducing behavior associated with hospital admission. Hosp Community Psychiatry 36:643-647, 1985
12. Tardiff K, Sweillam A: Assaultive behavior among chronic inpatients. Am J Psychiatry 139:212-215, 1982
13. Eichelmann B: Neurochemical bases of aggressive behavior. Psychiatr Ann 17:371-374, 1987
14. Newhill CE, Mulvey EP, Lidz CW: Characteristics of violence in the community by female patients seen in psychiatric emergency service. Psychiatr Services 46:785-789, 1995
15. Chandler JD, Chandler JE: The prevalence of neuropsychiatric disorders in a nursing home population. J Geriatr Psychiatr Neurol 1:71-76, 1988
16. Evans DA, Funkenstein HH, Albert MS, et al: Prevalence of Alzheimer's disease in a community population of older persons. JAMA 262:2551-2556, 1989
17. Duetsch LH, Bylsma FW, Rovner BW, et al: Psychosis and physical aggression in probable alzheimer's disease. Am J Psychiatry 148:1159-1163, 1991
18. Kunik ME, Yodofsky SC, Silver JM, Hales RE: Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 55:13-17, 1994 (suppl)
19. Junginger J: Command hallucinations and the prediction of dangerousness. Psychiatr Services 46:911-914, 1995
20. Ratey JJ, Gordon A: The psychopharmacology of aggression: Toward a new day. Psychopharmacol Bull 29:65-73, 1993
21. Wilson WH: Clinical review of clozapine treatment in a state hospital. Hosp Comm Psychiatry 43:700-703, 1992
22. Mallya AR, Roos PD, Roebuck-Colgan K: Restraint, seclusion, and clozapine. J Clin Psychiatry 53:395-397, 1992
23. Michals ML, Crismon ML, Roberts S, Childs A: Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 13:198-203, 1993
24. Ratey JJ, Leveroni C, Kilmer D, et al: The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 54:219-223, 1993
25. Volavka JL, Zito JM, Vitrai J, Czobor P: Clozapine effects on hostility and aggression in schizophrenia (letter). J Clin Psychopharmacol 13:287-289, 1993
26. Mesotten F, Suy E, Pietquin M, et al: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 99:445-449, 1989
27. Gelders YG, Heylen SL, Vanden Bussche G, et al: Pilot clinical investigation of risperidone in the treatment of psychotic patients [published erratum appears in Pharmacopsychiatry 24:38, 1991]. Pharmacopsychiatry 151:825-835, 1990
28. Czobor P, Volavka J: Quantitative EEG examination of effects of risperidone in schizophrenic patients. J Clin Psychopharmacol 13:332-342, 1993
29. Czobor P, Volavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 15:243-249, 1995
30. Kay SR, Opler LA, Fiszbein A: Positive and negative syndrome scale (PANSS). Rating manual. San Rafael, CA, Social and Behavioral Sciences Documents, 1987
31. Modell JG, Lenox RH, Weiner S: Inpatient clinical trial of lorazepam for the management of manic agiation. J Clin Psychopharmacol 5:109-113, 1985
32. Salzman C, Solomon D, Miyawaki E, et al: Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52:177-180, 1991
33. Teboul E, Chouinard G: A guide to benzodiazepine selection. Part II: Clinical aspects. Can J Psychiatry 36:62-73, 1991
34. Busto U, Sellers EM, Naranjo CA, et al: Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 315:854-859, 1986
35. Dietch JT, Jennings RK: Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 49:184-188, 1988
36. Lipinski JF, Keck PE, McElroy S: Beta-adrenergic antagonists in psychosis: Is improvement due to treatment of neuroleptic-induce akathisia? J Clin Psychopharmacol 8:409-416, 1988
37. Ratey JJ, Sorgi P, O'Driscoll GA, et al: Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: A double-blind, placebo-controlled study. J Clin Psychiatry 53:41-46, 1992
38. Alpert M, Allan ER, Citrome L, et al: A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 26:367-371, 1990
39. Ritrovato CA, Weber SA, Dufresne DL: Nadolol in the treatment of aggressive behavior associated with schizophrenia. Clin Pharm 8:132-135, 1989
40. Ratey JJ, Mikkelsen EJ, Smith B, et al: β-blockers in the severly and profundly mentally retarded. J Clin Psychopharmacol 6:103-107, 1986
41. Greendyke RM, Schuster DB, Wooton JA: Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 4:282-285, 1984
42. Yudofsky SC, Stevens L, Silver JM, et al: Propranolol in the treatment of rage and violent behavior with Korsakoff's psychosis. Am J Psychiatry 141:114-115, 1984
43. Mattes JA: Metoprolol for intermittent explosive disorder. Am J Psychiatry 142:1108-1109, 1985
44. Hakola HPA, Laulumma VA: Carbamazepine in treatment of violent schizophrenics (letter). Lancet 1:1358, 1982
45. Neppe VM: Carbamazepine in the psychiatric patient (letter). Lancet 2:334, 1982
46. Luchins DJ: Carbamazepine for the violent psychiatric patient (letter). Lancet 1:766, 1983
47. Yassa R, Dupont D: Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: A case report. Can J Psychiatry 28:566-568, 1983
48. Klein E, Bental E, Lerer B, Belmaker RH: Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 41:165-170, 1984
49. Okuma T, Yamashita I, Takahashi R, et al: A double-blind study of adjunctive Carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 80:250-259, 1989
50. Slater E, Beard A, Glithero E: The schizophrenic-like psychoses of epilepsy. Int J Psychiatry 1:6-30, 1965
51. Stevens JR, Hermann BP: Temporal lobe epilepsy, psychopathology, and violence: The state of the evidence. Neurology 31:1127-1132, 1981
52. Barrat ES: The use of anticonvulsants in aggression and violence. Psychopharmacol Bull 29:75-81, 1993
53. Post RM: Time course of clinical effects of carbamazepine: Implications for mechanisms of action. J Clin Psychiatry 49:35-46, 1988 (suppl 4)
54. Lee HK, Reddy TB, Travin S, Bluestone H: A trial of lithium citrate for the management of acute agitation of psychiatric inpatients: A pilot study [letter]. J Clin Psychopharmacol 12:361-361, 1992
55. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM: Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. J Clin Psychiatry 53:47-52, 1992
56. Glenn MB, Wroblewski B, Parziale J, et al: Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Physic Med Rehab 68:221-226, 1989
57. Craft M, Ismail IA, Krishnamurti D, et al: Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry 150:685-689, 1987
58. Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650-656, 1984
59. Platt JE, Campbell M, Green WH, Grega DM: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41:657-662, 1984
60. Bennett WG, Korein J, Kalmijn M, et al: Electroencephalogram and treatment of hospitalized aggressive children with haloperidol or lithium. Biol Psychiatry 18:1427-1440, 1983
61. Carman JS, Bigelow LB, Wyatt RJ: Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42:124-128, 1981
62. Dale PG: Lithium therapy in aggressive mentally subnormal patients. Br J Psychaitry 137:469-474, 1980
63. Smith DA, Perry PJ: Nonneuroleptic treatment of disruptive behavior in organic mental syndromes. Ann Pharmacother 26:1400-1408, 1992
64. Perry PJ, Alexander B, Liskow BI (eds): Psychotropic Drug Handbook, 6 ed. Cincinnati, OH, Harvey Whitney Books Company, 1991, p 253
65. Schipper J, Tulp MTM, Sijbesma H: Neurochemical profile of eltoprazine. Drug Metab Drug Interactions 8:85-114, 1990
66. Raghoebar M, Mak M, Cournot A, et al: Pharmacokinetics of eltoprazine in healthy male subjects after single dose and intravenous administration. Br J Clin Pharmacol 30:879-883, 1990
67. van Harten J, Mathlener IS, Raghoebar M: Pharmacokinetics of eltoprazine in healthy male subjects. Drug Metabol Drug Interact 8:149-158, 1990
68. Verhoeven WMA, Tuinier S, Sijben NAS, et al: Eltoprazine in mentally retarded self-injuring patients (letter). Lancet 340:1037-1038, 1992
69. Tiihonen J, Hakola P, Paanila J, Turtiainen M: Eltoprazine for aggression in schizophrenia and mental retardation (letter). Lancet 341:307, 1993
70. Kohen D: Eltoprazine for aggression in mental handicap (letter). Lancet 341:628-629, 1993